| Abstract: |
A number of clear themes emerged at the SNMMI 2016 meeting. FDG was widely celebrated as the molecule of the century. Combined with PET/CT, FDG has redefined but (paradoxically) also narrowed the focus of clinical nuclear medicine over the last 15 years. However, we are now seeing the introduction of new imaging agents and therapeutic agents that are entering or likely to enter routine clinical use. This will broaden the scope of nuclear medicine practice and put more emphasis on therapy and the concept of theranostics. This is a very welcome change in our field and one that we should all embrace. Goethe said, "Everything ends if it does not change." The current rapid evolution in our field promises an exciting future of continued change and new discoveries that benefit a broad range of diseases and conditions. Copyright © 2017 SNMMI; all rights reserved. |
